Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials

Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials

Background: Combined immune checkpoint inhibitor (ICI) treatment targeting PD-1 and CTLA-4 was suggested to yield clinical benefit over chemotherapy in malignant pleural mesothelioma (MPM), whereas aPD-1 monotherapy failed to provide benefit in phase-III trials. Success of ICI depends on the presenc...

Full description

Bibliographic Details
Main Authors: Joanne M. Mankor, Maria J. Disselhorst, Myrthe Poncin, Paul Baas, Joachim G.J.V. Aerts, Heleen Vroman
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:EBioMedicine
Subjects:
Malignant pleural mesothelioma
Immune checkpoint inhibitors
Immunotherapy
Immune monitoring
Nivolumab
Ipilimumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396420304163

Internet

http://www.sciencedirect.com/science/article/pii/S2352396420304163

Similar Items